Oritavancin: an update

Future Microbiol. 2018 Jun 1:13:727-729. doi: 10.2217/fmb-2017-0310. Epub 2018 May 25.

Authors

Greta Flüh¹, Harald Seifert^{2

3}, Achim J Kaasch¹

Affiliations

¹ Institute of Medical Microbiology & Hospital Hygiene, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
² Institute for Medical Microbiology, Immunology & Hygiene, University of Cologne, Cologne, Germany.
³ German Center for Infection Research (DZIF), partner site Bonn-Cologne, Cologne, Germany.

PMID: 29799267
DOI: 10.2217/fmb-2017-0310

No abstract available

Keywords: antimicrobial; commentary; oritavancin.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Anti-Bacterial Agents / pharmacology*
Bacteria / drug effects
Bacterial Infections / drug therapy*
Bacterial Infections / microbiology
Bacterial Physiological Phenomena / drug effects
Biofilms / drug effects
Humans
Lipoglycopeptides / pharmacology*

Substances

Anti-Bacterial Agents
Lipoglycopeptides
oritavancin